{"nctId":"NCT03117049","briefTitle":"Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)","startDateStruct":{"date":"2017-06-13","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"count":550,"armGroups":[{"label":"ONO-4538 group","type":"EXPERIMENTAL","interventionNames":["Drug: ONO-4538","Drug: Carboplatin","Drug: Paclitaxel","Drug: Bevacizumab"]},{"label":"Placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Carboplatin","Drug: Paclitaxel","Drug: Bevacizumab","Drug: Placebo"]}],"interventions":[{"name":"ONO-4538","otherNames":[]},{"name":"Carboplatin","otherNames":[]},{"name":"Paclitaxel","otherNames":[]},{"name":"Bevacizumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer\n* Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy\n* Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria\n* Subjects who are able to provide tumor tissue specimens.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1\n\nExclusion Criteria:\n\n* Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.\n* Subjects with known ALK translocations.\n* Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds\n* Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.\n* Subjects with multiple cancer.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)","description":"PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = \"date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first\" - \"date of randomization\" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"8.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"24.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR [as Assessed by the IRRC])","description":"ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR [as Assessed by the IRRC])","description":"DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"89.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR [as Assessed by the IRRC])","description":"The lower and upper limits of 95% CI for the median are censored value in the both groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response (BOR [as Assessed by the IRRC])","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":154,"n":273},"commonTop":["Alopecia","Constipation","Neutrophil count decreased","Peripheral sensory neuropathy","Decreased appetite"]}}}